Ovarian Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

NCCN Collaborative Projects in Advanced Ovarian Cancer
Can Ovarian RADS MRI Identify Ovarian Cancer in Indeterminate Masses?
FDA Accepts sNDA for Niraparib in First-Line Maintenance Treatment of Ovarian Cancer
Fox Chase Researchers Receive Grant to Study High-Grade Serous Ovarian Cancer
CMS to Expand Coverage of Next-Generation Sequencing for Ovarian or Breast Cancer
FDA Grants Priority Review to Olaparib/Bevacizumab as Maintenance Therapy for Ovarian Cancer
Proteomic Analysis Identifies ADNP Gene as Mediator of Cell Proliferation in Ovarian Cancer
Protein Targeted in Ovarian Cancer Stem Cells
Are Calreticulin Levels Related to Ovarian Cancer Prognosis?
Identifying a Novel Pathway to Platinum Resistance in Ovarian Cancer
Novel Adenovirus Plus Chemotherapy for Platinum-Resistant Ovarian Cancer
Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer
NCRI Conference: Early Testing for Levels of CA125 in Diagnosing Ovarian Cancer
Gift of $5M From Leonard A. Lauder to Advance Research in Ovarian Cancer
Does Trametinib Treatment Improve Outcomes in Rare Ovarian Cancer Subtype?
ESMO 2019: Activity of Cediranib Plus Olaparib in Platinum-Resistant Ovarian Cancer
Niraparib Approved by FDA for HRD-Positive Advanced Ovarian Cancer
ESMO 2019: ATR Inhibitor Plus Gemcitabine in High-Grade Serous Ovarian Cancer
ESMO 2019: Olaparib Plus Bevacizumab as Maintenance Therapy for Ovarian Cancer
ESMO 2019: PARP Inhibitor of Benefit in Newly Diagnosed Advanced Ovarian Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.